NCT00044486View on ClinicalTrials.gov

Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)

PHASE3CompletedINTERVENTIONAL

Enrollment

602

Participants

Timeline

Start Date

July 31, 2002

Primary Completion Date

December 31, 2004

Study Completion Date

April 30, 2005

Conditions

Leukemia, Myelocytic, AcuteMyelodysplastic SyndromesNeutropenia

Interventions

DRUG

Posaconazole oral suspension

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00044486 - Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | Biotech Hunter | Biotech Hunter